小分子甲基受体偏向激动剂,化合物17b是一种血管扩展剂和抗炎剂,在小鼠精密切割的肺切片中具有抗炎作用
William R Studley1, Emma Lamanna1, Katherine A Martin1
1Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
British journal of pharmacology
|September 2, 2023
概括
一种针对甲基受体 (FPRs) 的新型化合物显示出对肺动脉高血压 (PAH) 的承诺. 它有效地减少了血管收缩和炎症,为PAH患者提供了潜在的新治疗途径.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
- 炎症生物学 炎症生物学
背景情况:
- 肺动脉高血压 (PAH) 是一种致命的疾病,其特点是炎症和血管重塑.
- 目前用于PAH的血管扩张疗法可以改善血压,但不能改善存活率.
- 甲基受体 (FPR) 参与血管扩张和炎症解决,这表明PAH的治疗潜力.
研究的目的:
- 为了研究PFR偏差激素的血管扩张和抗炎作用,化合物17b,在肺血管.
- 在正常和炎症条件下,评估化合物17b在小鼠精密切割肺切片 (PCLS) 的疗效.
主要方法:
- 在小鼠PCLS中,为化合物17b和标准药物生成了度-反应曲线.
- 化合物17b的放松作用使用FPR抗剂和在炎症刺激 (TNF-α,LPS) 存在的情况下进行了评估.
- 用炎症刺激和化合物17b治疗的PCLS中测量了细胞因子释放.
主要成果:
- 在炎症条件下,化合物17b诱导了度依赖的血管扩张,其强度与里奥西瓜特相当,并且优于西尔德纳菲尔和伊洛普罗斯特.
- 化合物17b的血管扩张作用通过FPR1进行调解,而其抗炎作用则涉及FPR2.
- 化合物17b在标准药物效率较低的炎症条件下保持了有效性和强度,并且抑制了与PAH相关的细胞因子分泌.
结论:
- 化合物17b在肺血管中表现出持续的血管扩张和抗炎活性,即使在炎症条件下.
- 这种单一的FPR偏差激素对血管功能和炎症的双重作用是一个新的发现.
- 这些结果支持开发基于FPR的药物疗法,作为肺动脉高血压的有希望的新治疗策略.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...


